- Home
- GRF vs RNXT Comparison
GRF vs RNXT Comparison
Compare GRF & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRF | RNXT |
|---|---|---|
| Founded | 1989 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 37.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GRF | RNXT |
|---|---|---|
| Price | $10.97 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 3.0K | ★ 339.0K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | ★ $928,000.00 |
| Revenue This Year | N/A | $2,795.35 |
| Revenue Next Year | N/A | $272.69 |
| P/E Ratio | $8.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.93 | $0.70 |
| 52 Week High | $10.19 | $1.69 |
Technical Indicators
Market Signals| Indicator | GRF | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 53.98 | 51.36 |
| Support Level | $10.36 | $0.97 |
| Resistance Level | $11.05 | $1.08 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 49.75 | 39.06 |
Price Performance
Historical ComparisonAbout GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.